Walgreens has been sued by Arkansas Attorney General Leslie Rutledge, and the case was filed earlier this week. In her filing, she claimed that the pharmacy chain company played a big part in making the opioid crisis situation in the state worse.
Rutledge accused Walgreens of rendering a large number of orders for painkillers, and most of them are suspicious. The lawyer said that this is a violation of Arkansas’ Deceptive Trade Practices Act.
The lawsuit against Walgreens
The lawsuit was filed in Pulaski County Court, and it was stated that the pharmacy did not do enough to make sure that the prescriptions are legitimate and not questionable. It was said that because of Walgreens' failure to monitor the orders, large amounts of the regulated drug were distributed in Arkansas, as per Arkansas Democrat Gazelle.
"Walgreens has a legal responsibility to report suspicious orders and suspicious prescriptions," the attorney general said. "By failing to do so they enabled the black market of prescription drugs to increase dramatically, thus leading to more, greater addiction and more lives lost in the state of Arkansas."
As stated in the lawsuit, from 2006 to 2014, Walgreens fulfilled orders of over 142 million dosages of oxycodone and hydrocodone in the state. Rutledge said that this big amount should have alerted the company to the fact that suspicious orders were being placed.
It was added that such quantities that were distributed in Arkansas far exceeded the normal amount that could be consumed for medical legit purposes. “Walgreens failed to report and halt those orders and instead increased the number of pills distributed,” the statement from the suit reads.
With the filing, the state is seeking a directive that will force Walgreens to act responsibly and comply with federal and state laws. It is also seeking appropriate civil penalties for every violation that the company may have committed against the state’s consumer protection laws.
Walgreens denies the allegations
Walgreens refuted the accusations and stated that it never produced or marketed opioids. The company’s spokesperson further told FOX Business that they never sold the said drug to pain clinics, online pharmacies, and 'pill mills' that worsened the opioid crisis.
"Prior to 2014, we delivered opioids only to our own pharmacies, and the only place we ever sold FDA-approved opioid medications was at the pharmacy counter when presented with valid prescriptions written by DEA-licensed physicians for legitimate medical needs," the firm’s spokesperson said.
Finally, he added that the company’s pharmacists always evaluate and take the law into consideration before deciding whether to fill a prescription for controlled substances.


Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round
Kawasaki Heavy Shares Slide on Report of ¥200 Billion Capital Raise Plan
TetherMax Rebranding Highlights Official Exchange Partnerships as Foundation of Trust
Norway Offshore Oil Workers Reach Wage Deal, Averting Strike
SK Holdings, KKR Launch $1.3B Renewable Energy Venture in South Korea
Trump Reports $1.4 Billion in Crypto Income as Digital Assets Become Top Wealth Source
Apple Eyes Chinese Memory Chips as AI Shortage Pressures iPhone Supply Chain
Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal
Chinese Copper Foil Maker Londian Files U.S. IPO as EV Battery Demand Grows
Super Micro Employees Detained in Taiwan AI Server Export Investigation
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks
Suncorp Cuts 2026 Premium Growth Forecast as Australia, New Zealand Markets Weaken
ShareChat Eyes 2027 IPO After Reaching Operational Profitability, Report Says
Meta Stock Jumps as AI Cloud Expansion Challenges AWS, Microsoft, and Google
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat
Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 



